Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02174549 · ClinicalTrials.gov registry record · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
A Phase 1 study of Hepatocellular Carcinoma and Neuroendocrine Tumors, sponsored by Teclison.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 2
- Study locations
NCT02174549 is a Phase 1 study of Hepatocellular Carcinoma and Neuroendocrine Tumors that is actively recruiting participants, run by Teclison. The registered enrollment target is 25 participants, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (90% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT02174549, a Phase 1 study of Hepatocellular Carcinoma and Neuroendocrine Tumors, is actively recruiting participants, sponsored by Teclison.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase 1 study is to determine the optimal dose and tolerability of a hypoxia-activating agent, tirapazamine, when it is combined with embolization in liver cancer. Liver cancer patients who are Child-Pugh score A, suitable for embolization with tumor no more than 4 nodules are eligible. Tirapazamine will be given by intra-arterial injection before embolization. Treatment effect is evaluated by MRI based on mRECIST criteria. Repeat treatment is necessary only if disease progression. Dose escalation cohort has been completed. Expansion cohort is open for metastatic liver dominant neuroendocrine tumor.
Conditions Studied
Interventions
- DRUG Tirapazamine
- PROCEDURE Conventional Transarterial Embolization (TAE)
Study Locations (2)
California
- Stanford University - Palo Alto
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2014-09 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02174549
The ClinicalTrials.gov registry entry for NCT02174549 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (90% lower). The listed sponsor is Teclison, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Tirapazamine is the first listed.
NCT02174549 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02174549 about?
NCT02174549 is a clinical study titled "Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer". This phase 1 study is to determine the optimal dose and tolerability of a hypoxia-activating agent, tirapazamine, when it is combined with embolization in liver cancer. Liver cancer patients who are Child-Pugh score A, suitable for embolization with tumor no more than 4 nodules are eligible. Tirapaz...
What is the current status of trial NCT02174549?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2014-09. Estimated completion is 2025-12-31.
What conditions does trial NCT02174549 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma, Neuroendocrine Tumors, Gastrointestinal Cancer Metastatic.
What interventions are being tested in trial NCT02174549?
The interventions under investigation include: Tirapazamine (DRUG), Conventional Transarterial Embolization (TAE) (PROCEDURE).
Who is sponsoring clinical trial NCT02174549?
This trial is sponsored by Teclison, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02174549 being conducted?
This trial has 2 study locations across California, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
RECRUITING · Phase 1
-
Cryoablation and Arterial Infusion of SD-101 in Combination with Durvalumab and Tremelimumab
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.